Stevanato Group Achieves 8% Revenue Growth and Expands Margins in Q2 2025

Stevanato Group reported Q2 2025 revenue of €280.0 million, an 8% increase YoY, driven by a 10% rise in its Biopharmaceutical and Diagnostic Solutions segment. High-value solutions made up 42% of total revenue, with gross profit margin increasing 210 basis points to 28.1%. The company maintains its FY2025 guidance, expecting revenue of €1.160 billion to €1.190 billion and adjusted EBITDA of €288.5 million to €301.8 million.